George Praveen, Srivastava Mukta C, Ludmir Jonathan, Reed Robert M, Tewelde Semhar Z, Gupta Anuj, McCurdy Michael T
Department of Internal Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Division of Cardiology, University of Maryland School of Medicine, Baltimore, MD, USA.
Case Rep Cardiol. 2017;2017:8407530. doi: 10.1155/2017/8407530. Epub 2017 Feb 5.
Cardiac dysfunction is a common complication of sepsis in individuals with preexisting coronary disease and portends a poor prognosis when progressing to ischemic cardiogenic shock. In this setting, maximal medical therapy in isolation is often inadequate to maintain cardiac output for patients who are poor candidates for immediate revascularization. Furthermore, the use of vasopressors and inotropes increases myocardial demand and may lead to further injury. Percutaneous ventricular assist devices provide a viable option for management of severe shock with multiorgan failure. The Impella is one of several novel mechanical support systems that can effectively augment cardiac output while reducing myocardial demand and serve as a bridge to recovery from severe hemodynamic compromise. This case report describes the successful utilization of the Impella 2.5 in a patient with baseline profound anemia and coronary artery disease (CAD) presenting in combined distributive and cardiogenic shock associated with a type 2 myocardial infarction complicating sepsis.
心脏功能障碍是患有冠状动脉疾病个体脓毒症的常见并发症,进展为缺血性心源性休克时预后不良。在这种情况下,对于不适合立即进行血运重建的患者,单纯的最大程度药物治疗往往不足以维持心输出量。此外,使用血管升压药和正性肌力药物会增加心肌需求,并可能导致进一步损伤。经皮心室辅助装置为管理伴有多器官功能衰竭的严重休克提供了一种可行的选择。Impella是几种新型机械支持系统之一,可有效增加心输出量,同时降低心肌需求,并作为从严重血流动力学损害中恢复的桥梁。本病例报告描述了Impella 2.5在一名基线存在严重贫血和冠状动脉疾病(CAD)的患者中的成功应用,该患者出现与脓毒症并发的2型心肌梗死相关的混合性分布性和心源性休克。